Driving the Next Generation of Oncology Diagnostics & Therapeutics:
We Cannot Do It Alone

illumina logo engage

Thursday 28th of April, 2022 | 6.00pm GMT | London, UK | In-Person Event Only

Welcome to this exclusive event providing senior leaders in pharma and biotechs with an opportunity to hear from innovative start-ups and fellow biopharma companies on how they are actioning genomics to achieve long-term strategic stability and clinical success in oncology therapeutic development.

This is your chance to discover the latest biomarker and CDx strategies to guarantee broader patient adoption of oncology therapeutics and how Illumina is working to bridge the different ecosystems across the cancer care continuum, from early innovation to patient care, to improve the cancer patient journey.

Join this Engager to connect and network over appetizers and drinks with Directors, Heads & C-Level Executives within the translational medicine and clinical development arena. Share your goal of improving health outcomes in oncology and support one another in developing the next generation of oncology therapeutics.


Bobby Kaura

Director, Illumina for Start-Ups, Global Ecosystem Development


Flora Berisha

Head of Dx Strategic Partnering, Oncology

Janssen, Global R&D

Jason Yip


Tailor Bio

Megan Townsend

Business Development Manager, CDx Partnerships



Please Note: This is an in-person only event taking place at the Savage Garden Rooftop Bar in London, and virtual attendance will not be available


Savage Garden Rooftop Bar

Floor 12, 7 Pepys St, London EC3N 4AF

Check Out Their Website Here



illumina logo engage

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.